Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD

Neuropharmacology

Volumn 57, Issue 7-8, 2009, Pages 731-733

  Nemoda, Zsofia ^a   Angyal, Nora ^a   Tarnok, Zsanett ^b   Gadoros, Julia ^b   Sasvari Szekely, Maria ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Vadaskert Child and Adolescent Psychiatric Clinic   (Hungary)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Carboxylesterase 1 (CES1); Methylphenidate (MPH); Pharmacogenetics

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; SCHOOL CHILD;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; GENE FREQUENCY; HUMANS; MALE; METHYLPHENIDATE; POLYMORPHISM, GENETIC;

EID: 70350217593     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.08.014     Document Type: Article

References (11)

1. Biederman J., and Spencer T.J. Psychopharmacological interventions. Child Adolesc. Psychiatr. Clin. N. Am. 17 2 (2008) 439-458 (xi)
2. DuPaul G.J. ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretations (1998), Guilford Press, New York
3. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 3 6 (2006) 6
4. Kereszturi E., Tarnok Z., Bognar E., Lakatos K., Farkas L., Gadoros J., Sasvari-Szekely M., and Nemoda Z. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am. J. Med. Genet. B 147B 8 (2008) 1431-1435
5. Marsh S., Xiao M., Yu J., Ahluwalia R., Minton M., Freimuth R.R., Kwok P.Y., and McLeod H.L. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84 4 (2004) 661-668
6. Michelson D., Read H.A., Ruff D.D., Witcher J., Zhang S., and McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 46 2 (2007) 242-251
7. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., and Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 164 (2007) 942-948
8. Singh I. Beyond polemics: science and ethics of ADHD. Nat. Rev. Neurosci. 9 12 (2008) 957-964
9. Stein M.A., and McGough J.J. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc. Psychiatr. Clin. N. Am. 17 2 (2008) 475-490 (xi-xii)
10. Sun Z., Murry D.J., Sanghani S.P., Davis W.I., Kedishvili N.Y., Zou Q., Hurley T.D., and Bosron W.F. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J. Pharmacol. Exp. Ther. 310 2 (2004) 469-476
11. Zhu H.J., Patrick K.S., Yuan H.J., Wang J.S., Donovan J.L., DeVane C.L., Malcolm R., Johnson J.A., Youngblood G.L., Sweet D.H., Langaee T.Y., and Markowitz J.S. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82 6 (2008) 1241-1248